COVID-19: State of the Vaccination
- 15 October 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs & Therapy Perspectives
- Vol. 37 (11), 508-518
- https://doi.org/10.1007/s40267-021-00869-4
Abstract
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting coronavirus disease 2019 (COVID-19) pandemic has led to rapid vaccine development and emergency use (EU) rollout. Six vaccines, including two using novel mRNA technology, are EU-listed by the World Health Organisation, and promising published trial data are available for nine more. While efficacy is good, there are various barriers to their global use. Long-term safety and immunogenicity data are being collected along the way.This publication has 24 references indexed in Scilit:
- Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant PersonsThe New England Journal of Medicine, 2021
- SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunityRespiratory Medicine, 2021
- SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidatesnpj Vaccines, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineThe New England Journal of Medicine, 2021
- Covid-19: Countries are learning what others paid for vaccinesPublished by BMJ ,2021
- COVID-19 vaccination in immunocompromised patientsClinical Rheumatology, 2021
- Safety and efficacy of the Russian COVID-19 vaccine: more information neededThe Lancet, 2020
- Cellular immune responses to covid-19BMJ, 2020
- SOBERANA, Cuba’s COVID-19 Vaccine Candidates: Dagmar García-Rivera PhD Director of Research, Finlay Vaccine InstituteMEDICC Review, 2020